Effects of pravastatin on mediators of vascular function in a mouse model of soluble Fms-like tyrosine kinase-1–induced preeclampsia
Authors:
- Karin A. FoxKFKarin A. Fox
- Monica LongoMLMonica Longo
- Esther TamayoETEsther Tamayo
- Talar KechichianTKTalar Kechichian
- Egle BytautieneEBEgle Bytautiene
- Gary D.V. HankinsGHGary D.V. Hankins
- George R. SaadeGSGeorge R. Saade
- Maged M. CostantineMCMaged M. Costantine
- 1 October 2011
- journal article
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 205 (4) , 366.e1-366.e5
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- Pravastatin induces placental growth factor (PGF) and ameliorates preeclampsia in a mouse modelProceedings of the National Academy of Sciences, 2010
- Vitamins C and E to Prevent Complications of Pregnancy-Associated HypertensionNew England Journal of Medicine, 2010
- The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trialsBMJ, 2009
- Hypertensive Pregnancy Disorders and Subsequent Cardiovascular Morbidity and Type 2 Diabetes Mellitus in the MotherHypertension, 2009
- Shared Constitutional Risks for Maternal Vascular-Related Pregnancy Complications and Future Cardiovascular DiseaseHypertension, 2008
- The change in concentrations of angiogenic and anti-angiogenic factors in maternal plasma between the first and second trimesters in risk assessment for the subsequent development of preeclampsia and small-for-gestational ageThe Journal of Maternal-Fetal & Neonatal Medicine, 2008
- Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysisBMJ, 2007
- Inflammation, Atherosclerosis, and Coronary Artery DiseaseNew England Journal of Medicine, 2005
- Clinical Pharmacokinetics of PravastatinClinical Pharmacokinetics, 2000
- Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol LevelsNew England Journal of Medicine, 1998